Lv5
832 积分 2024-09-01 加入
Risk Stratification for the Prognosis of Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma
17小时前
已完结
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study
17小时前
已完结
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma
17小时前
已完结
VISION, TheraP, LuTectomy and beyond – is there a role for lutetium therapy in biochemical recurrence?
17小时前
已完结
Real-World Treatment Patterns and Survival in People with Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States
17小时前
已完结
Evaluation of the Effects of Enzalutamide and Abiraterone Acetate on Sarcopenia in Metastatic Castration-Sensitive Prostate Cancer
17小时前
已完结
Refining the CHAARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer
17小时前
已完结
Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients
17小时前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
17小时前
已完结
Recent advancements in personalized management of prostate cancer biochemical recurrence after radical prostatectomy
17小时前
已完结
皖公网安备34019202002308
